Specimen validity testing (SVT) is performed on a urine drug screen specimen to measure the pH, and specific gravity, ensuring that no adulterant has been added to the urine specimen.
Various types of adulterants are detected quickly with the most accurate results. In the testing, the results can be achieved within minutes and the specimen validity test will provide the most precise urine test result.
Increasing cases of drug abuse across the globe and rapid technological advancements in testing technology are major factors expected to drive the growth of the global specimen validity testing market. Government of developed and developing countries is focused on controlling the use of illegal drugs. According to data released by the Substance Abuse and Mental Health Services Administration (SAMHSA) in 2012, nearly 23 million Americans aged 12 years or older participated in illicit drug use in the past month. That accounts for 8.7% of the population, making it a major public health problem in the US. Approach towards safeguarding the workplace environment and enhancing patient monitoring is resulting in demand for various screening methods. Workforce substance abuse is on the rise according to Quest Diagnostics report in 2016, 4.2% of all urine tests came back positive, up from 4.0 percent in 2015 and the highest rate since 2004's 4.5 percent. Positive oral drug tests increased nearly 75 percent to 8.9 percent in 2016, up from 5.1 percent in 2013. Rising cases of drug trafficking at the airport and increasing use of specimen testing in order to detect for substitution, adulteration, or dilution of drugs in specimen this is expected to impact the growth of specimen validity testing market. Major players are focused on R&D activities and introduction of innovative solutions this is expected to support the market growth. In 2018, Premier Biotech Inc. a leading manufacturer of rapid drug testing diagnostic devices received approval from U.S. Food and Drug Administration (FDA) for the drugs amphetamine, cocaine, marijuana, methamphetamine, opiates, and phencyclidine for OralTox, its flagship, patented rapid oral fluid drug screen device. This is expected to help the company to enhance the customer base and increase the revenue share.
Factors such as stringent government regulations related to product approval and introduction of alternative drug testing are factors expected to hamper the growth of global specimen validity testing market. In addition, lack of skilled labor in developing countries is expected to challenge the growth of target market. However, increasing point-of-care specimen validity testing and high spending by the players for introduction of innovative products are factors expected to create new opportunities for players operating in the specimen validity testing market over the forecast period. In addition, increasing partnerships and agreements between regional and international players is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global specimen validity testing market due to rising awareness related to drug abuse. Chancing government regulations related to drug testing and availability of advanced infrastructure in order to support the advanced testing methods are factors expected to support the growth of specimen validity testing market. In 2016, CDC published the guideline for prescribing opioids for chronic pain. They recommends that urine drug testing should be performed initially and at least annually for all patients. In addition, high adoption from workplaces, criminal justice, and agencies for law enforcement is expected to impact the growth of the regional market. Major players are focused on enhancing the business through strategic acquisitions this is expected to help the company to enhance the customer base and increase the revenue share. This is expected to augment the specimen validity testing market growth.
The market in Asia Pacific is expected to witness faster growth in the specimen validity testing market in the forecast period due to increasing government focus on introduction of advanced testing techniques. Major players focus on tracing the untapped market in developing countries and increasing partnership are factors expected to support the growth of target market. Favorable business policies and emergence of small & mid-size enterprises with innovative solutions this is expected to support the regional market growth.
The global specimen validity testing market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Specimen Validity Testing Market Segment Analysis, 2019
The global specimen validity testing market is segmented into product & service, type, and end use. The product & service segment is bifurcated into reagents, calibrators, and controls, assay kits, and disposables. Among product & service the assay kits segment is expected to witness faster growth in the target market. The end use segment is divided into workplaces, drug screening laboratories, criminal justice and law enforcement agencies, pain management centers, drug rehabilitation centers, and other. Among end use the pain management centers segment is expected to account for noticeable revenue share in the global specimen validity testing market. The players profiled in the report are Thermo Fisher, Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, Premier Biotech, LabCorp, Quest Diagnostics, Alere Toxicology, ACM Global Laboratories, Clinical Reference Laboratory (CRL), SureHire, and CannAmm.
Market By Product & Service
Market By Type
Market By End Use
Drug Screening Laboratories
Criminal Justice and Law Enforcement Agencies
Pain Management Centers
Drug Rehabilitation Centers
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Increasing cases of drug abuse across the globe and rapid technological advancements in testing technology are major factors expected to drive the growth of global specimen validity testing market.
In type the Rapid/POC testing segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Thermo Fisher, Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, and Premier Biotech.
The North America is expected to account for major revenue share in the global market.
In end use the drug screening laboratories segment is growing at faster pace.
Factors such as stringent government regulations related to product approval and introduction of alternative drug testing are factors expected to hamper the growth of global specimen validity testing market.